Q2 FY2026 EarningsQ2 FY2026 revenue of $2.51M significantly beat the $0.42M consensus, driven by higher-than-expected grant funding from the Department of War. GAAP Net Income was $74.1M ($2.02/share), far exceeding the projected net loss of -$16.4M, though this was primarily due to a one-time $91.0M non-cash gain from the fair value adjustment of a convertible loan. Excluding this non-cash item, the underlying operating loss was $10.3M, slightly wider than the $9.8M consensus EBIT loss due to increased stock-based compensation.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Armata Pharmaceuticals(ARMP) the Revenue is 2.51 M (+15.72%), Beat estimate;the EBIT is -10.31 M (--%), Miss estimate;the EPS is 1.2 (+365.6%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B15.72%
0.00B80.64%
+0.00B96.36%
EBITMiss expectations
-0.01B--
-0.01B--
-0.00B--%
EPSExceed expectations
1.195365.56%
-0.4451.11%
+1.6400364.45%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf